HLA-A and head and neck squamous cell carcinoma: In addition, we were able to demonstrate a statistically significant, independent association of HLA-A*02 with longer PFS in a multivariate setting, which was not analyzed in the manuscript by Tisch et al. In line with this observation, an analysis of OS in the HNSCC with the Cancer Genome Atlas cohort backed the strong trend for longer survival of HLA-A*02-positive patients (p = 0.146), but it also did not analyze PFS [21].